ZVSA vs. KPRX, IMNN, EDSA, HUGE, PIRS, RDHL, AVTX, MIRA, ELAB, and GHSI
Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Kiora Pharmaceuticals (KPRX), Imunon (IMNN), Edesa Biotech (EDSA), FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), RedHill Biopharma (RDHL), Avalo Therapeutics (AVTX), MIRA Pharmaceuticals (MIRA), Elevai Labs (ELAB), and Guardion Health Sciences (GHSI). These companies are all part of the "pharmaceutical preparations" industry.
ZyVersa Therapeutics (NASDAQ:ZVSA) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.
In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 1 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 1.87 beat Kiora Pharmaceuticals' score of 0.54 indicating that ZyVersa Therapeutics is being referred to more favorably in the media.
ZyVersa Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
Kiora Pharmaceuticals' return on equity of 17.90% beat ZyVersa Therapeutics' return on equity.
Kiora Pharmaceuticals received 10 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 68.42% of users gave Kiora Pharmaceuticals an outperform vote.
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 0.7% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 0.9% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ZyVersa Therapeutics presently has a consensus target price of $120.00, indicating a potential upside of 2,329.15%. Kiora Pharmaceuticals has a consensus target price of $2.00, indicating a potential upside of 305.68%. Given ZyVersa Therapeutics' higher probable upside, research analysts plainly believe ZyVersa Therapeutics is more favorable than Kiora Pharmaceuticals.
Summary
Kiora Pharmaceuticals beats ZyVersa Therapeutics on 7 of the 11 factors compared between the two stocks.
Get ZyVersa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZyVersa Therapeutics Competitors List
Related Companies and Tools
